Open AccessActivity of a Novel Cyclic Lipopeptide, CB-183,315, against Resistant Clostridium difficile and Other Gram-Positive Aerobic and Anaerobic Intestinal Pathogens
Author(s) -
David R. Snydman,
Nilda V. Jacobus,
Laura McDermott
Publication year - 2012
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.06257-11
Subject(s) - microbiology and biotechnology , clostridium difficile , peptostreptococcus , vancomycin , metronidazole , enterococcus , lipopeptide , clostridium , biology , staphylococcus aureus , anaerobic bacteria , antibiotics , bacteria , genetics
We evaluated the activity of CB-183,315 againstClostridium difficile , including strains that are resistant to fluoroquinolones and metronidazole and with elevated MICs to vancomycin as well as other Gram-positive intestinal pathogens. The MICs of CB-183,315 against allC. difficile isolates were ≤1 μg/ml. CB-183,315 had greater activity than vancomycin and metronidazole againstC. difficile isolates and was more active than the comparators against vancomycin-resistant enterococcus (VRE). CB-183,315 also had excellent activity against methicillin-resistantStaphylococcus aureus (MRSA), otherClostridium spp., andPeptostreptococcus spp.